Clinical Trial: Efficacy and Safety Study of HS-10542 for IgA Nephropathy

U.S., March 17 -- ClinicalTrials.gov registry received information related to the study (NCT07474636) titled 'Efficacy and Safety Study of HS-10542 for IgA Nephropathy' on Feb. 26.

Brief Summary: This is a multicenter, randomized, double-blind, parallel, placebo-controlled study and is being conducted to evaluate the efficacy and safety of HS-10542 capsules for primary IgA nephropathy.

Study Start Date: March 17

Study Type: INTERVENTIONAL

Condition: IgAN Immunoglobulin A Nephropathy (IgAN) Glomerular Disease

Intervention: DRUG: HS-10542 High Dose

Drug: HS-10542 High Dose, QD

DRUG: HS-10542 Low Dose

Drug: HS-10542 Low Dose, QD

DRUG: Placebo

Placebo, QD

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Jiangsu Hansoh Pharmaceutica...